查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1751199

抗真菌藥物市場規模、佔有率、趨勢分析報告：按藥物類別、適應症、劑型、分銷管道、地區、細分市場預測，2025-2030 年

Antifungal Drugs Market Size, Share & Trends Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines), By Indication, By Dosage Form, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

抗真菌藥物市場的成長與趨勢：

根據 Grand View Research 的最新報告，到 2030 年全球抗真菌藥物市場規模預計將達到 205.2 億美元。

預計2025年至2030年，該市場將以3.92%的複合年成長率擴張。全球真菌感染疾病盛行率的上升是推動市場成長的關鍵因素。此外，近年來，由於免疫抑制劑和抗腫瘤藥物、假體裝置和植入物以及廣譜抗生素的使用增加，真菌感染疾病的發生率也有所上升。

根據美國疾病管制與預防中心2017年發布的統計數據，全球每年新增近22萬例隱球菌腦膜炎（一種腦部感染疾病）病例，估計每年導致18.1萬人死亡。由於愛滋病毒/愛滋病的高發性，大多數死亡病例發生在撒哈拉以南非洲地區。這表明，由於全球真菌感染疾病的高發性，對抗真菌藥物存在潛在的需求。

為遏止新冠肺炎疫情蔓延，許多國家的政府當局下令在全國實施封鎖。同樣，世界各地的衛生系統也在努力維持供應鏈。供應鏈延遲也影響了對抗真菌藥物的需求。全球老齡人口的成長可能會刺激對抗真菌藥物的需求，以治療機會性真菌感染疾病，因為老年人更容易感染愛滋病毒和癌症等感染疾病和慢性病。由於難以診斷、死亡率和發病率高的真菌感染疾病增加，預計到2030年對抗真菌藥物的需求仍將保持強勁。

抗真菌藥物市場報告重點

  • Azole類藥物將佔據市場主導地位，2024 年的銷售佔有率將達到 47.57%。這種主導地位是由於 Noxafil、Bufend、 Diflucan和 Cresemba 等主要治療藥物的影響。
  • 念珠菌症在 2024 年佔據了最大的市場佔有率，這是因為念珠菌病在免疫力缺乏的患者中的患病率不斷增加，且復發性感染率很高。
  • 預計預測期內麴菌症的複合年成長率將顯著提升。麴菌症是由一種名為麴菌症的黴菌引起的感染疾病，通常會影響呼吸系統。
  • 口服劑型在 2024 年佔據市場主導地位。這是因為某些抗真菌藥物是專為口服給藥而設計的，以確保正確吸收。
  • 2024年，醫院藥局將引領市場。醫院藥房在確保患者即時獲得基本藥物方面發揮著至關重要的作用。它們服務於門診病人和住院患者，促進真菌感染疾病的無縫治療。
  • 北美將主導市場，到 2024 年將佔據 40.62% 的佔有率。該地區的主導地位可歸因於高度發展的醫療保健基礎設施、可負擔性和不斷增強的意識。
  • 由於目標人口眾多、市場不斷擴大的醫療設施以及主要市場參與者的投資不斷增加，預計亞太地區在預測期內將顯著成長。

目錄

第1章調查方法與範圍

第2章執行摘要

抗真菌藥物市場變數、趨勢和範圍

  • 市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

抗真菌藥物市場：按藥物類別的業務分析

  • 2024 年及 2030 年各藥品類別的市場佔有率
  • 藥品類別細分儀表板
  • 2018-2030 年藥品類別市場規模、預測及趨勢分析
  • Azole
  • Echinocandins
  • Polyenes
  • Allylamines
  • 其他

抗真菌藥物市場：按適應症分類的業務分析

  • 2024 年及 2030 年各適應症市場佔有率
  • 指示細分儀表板
  • 市場規模、預測與趨勢分析（2018-2030 年）
  • 皮膚絲狀菌症
  • 麴菌症
  • 念珠菌症
  • 其他

抗真菌藥物市場：按劑型分類的業務分析

  • 2024 年及 2030 年各劑型市場佔有率
  • 劑型細分細分儀表板
  • 市場規模、預測與趨勢分析（按劑型，2018-2030 年）
  • 口服藥物
  • 軟膏
  • 粉末
  • 其他

抗真菌藥物市場：按分銷管道分類的業務分析

  • 2024 年和 2030 年按分銷管道分類的市場佔有率
  • 分銷通路細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 醫院藥房
  • 零售藥局
  • 其他藥局

抗真菌藥物市場：區域估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018年至2030年市場規模與預測趨勢分析：
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭態勢

  • 參與企業概況
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/列表
    • Novartis AG
    • Pfizer, Inc.
    • Bayer AG
    • Sanofi
    • Merck &Co., Inc.
    • GSK plc.
    • Abbott
    • GLENMARK
    • Enzon Pharmaceuticals, Inc.
    • Astellas Pharma, Inc.
Product Code: GVR-1-68038-293-8

Antifungal Drugs Market Growth & Trends:

The global antifungal drugs market size is expected to reach USD 20.52 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 3.92% from 2025 to 2030. The increasing incidence of fungal infections worldwide is the key factor stoking the growth of the market. In addition, the rise in the adoption of immunosuppressive and antineoplastic agents, prosthetic devices and grafts, and broad-spectrum antibiotics has resulted in an increased incidence of fungal infections in recent years.

According to statistics published by the Centers for Disease Control and Prevention in 2017, it has been estimated that every year, nearly 220,000 new individuals are affected by cryptococcal meningitis, which is a brain infection and has resulted in 181,000 deaths per year around the world. Most of the deaths were reported in sub-Saharan Africa, due to the high prevalence of HIV/AIDS. This indicates the potential demand for antifungal drugs due to the high prevalence of mycological infections around the globe.

The government authorities in many countries had ordered nationwide lockdowns in order to contain the spread of COVID-19. Similarly, health systems in a number of countries around the world were having trouble maintaining their supply chains. The slowness of the supply chain has also impacted the demand for antifungal medications. As aged people are more prone to infectious diseases and chronic conditions, including HIV and cancer, the rise in the geriatric population worldwide is likely to stir up the demand for antifungals to treat opportunistic fungal infections. The demand for fungistatic agents is estimated to remain strong through 2030 due to mounting cases of fungal infections that are difficult to diagnose, yielding high mortality and morbidity rates.

Antifungal Drugs Market Report Highlights:

  • The Azoles drug class segment dominated the market and accounted for a revenue share of 47.57% in 2024. This dominance is attributed to the influence of key therapeutic agents, including noxafil, vfend, diflucan, and cresemba.
  • The Candidiasis segment held the largest market share in 2024 due to rising incidence of the disease in immunocompromised patients and high rate of recurrent infections.
  • Aspergillosis is expected to register significant CAGR during the forecast period. Aspergillosis is an infection caused by mold called aspergillosis, which usually affects the respiratory system.
  • Oral drugs dosage form led the market in 2024. This is attributed to the fact that certain antifungal medications are designed for oral administration to ensure proper ingestion.
  • Hospital pharmacies led the market in 2024. Hospital pharmacies play a key role in ensuring immediate access to crucial medications. They serve both out-patient and in-patient services, facilitating the seamless treatment of fungal infections.
  • North America dominated the market and accounted for 40.62% share in 2024. This region dominance is attributed to the highly developed healthcare infrastructure, better affordability, and increasing awareness.
  • Asia Pacific is anticipated to witness significant growth during the forecast period. This is owing to the presence of large target population, developing healthcare facilities, and increase in investments by leading market players.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Indication
    • 1.2.3. Dosage Form
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Antifungal Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Antifungal Drugs Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Azoles
    • 4.4.1. Azoles Market, 2018 - 2030 (USD Million)
  • 4.5. Echinocandins
    • 4.5.1. Echinocandins Market, 2018 - 2030 (USD Million)
  • 4.6. Polyenes
    • 4.6.1. Polyenes Market, 2018 - 2030 (USD Million)
  • 4.7. Allylamines
    • 4.7.1. Allylamines Market, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Other Drug Class Market, 2018 - 2030 (USD Million)

Chapter 5. Antifungal Drugs Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2024 & 2030
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 5.4. Dermatophytosis
    • 5.4.1. Dermatophytosis Market, 2018 - 2030 (USD Million)
  • 5.5. Aspergillosis
    • 5.5.1. Aspergillosis Market, 2018 - 2030 (USD Million)
  • 5.6. Candidiasis
    • 5.6.1. Candidiasis Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Antifungal Drugs Market: Dosage Form Business Analysis

  • 6.1. Dosage Form Market Share, 2024 & 2030
  • 6.2. Dosage Form Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2018 to 2030 (USD Million)
  • 6.4. Oral Drugs
    • 6.4.1. Oral Drugs Market, 2018 - 2030 (USD Million)
  • 6.5. Ointments
    • 6.5.1. Ointments Market, 2018 - 2030 (USD Million)
  • 6.6. Powders
    • 6.6.1. Powders Market, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Antifungal Drugs Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2030
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.6. Other Pharmacies
    • 7.6.1. Other Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Antifungal Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Antifungal Drugs Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. U.S. Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. Uk Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Japan Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. China Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Antifungal Drugs Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Novartis AG
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Pfizer, Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Bayer AG
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Sanofi
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Merck & Co., Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. GSK plc.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Abbott
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. GLENMARK
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Enzon Pharmaceuticals, Inc.
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Astellas Pharma, Inc.
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Antifungal drugs market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 5. Global antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 6. Global antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 7. Global antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8. North America antifungal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 9. North America antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 10. North America antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 11. North America antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 12. North America antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13. U.S. antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 14. U.S. antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 15. U.S. antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 16. U.S. antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17. Canada antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 18. Canada antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 19. Canada antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 20. Canada antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 21. Mexico antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 22. Mexico antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 23. Mexico antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 24. Mexico antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25. Europe antifungal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 26. Europe antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 27. Europe antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 28. Europe antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 29. Europe antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30. UK antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 31. UK antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 32. UK antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 33. UK antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34. Germany antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 35. Germany antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 36. Germany antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 37. Germany antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 38. France antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 39. France antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 40. France antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 41. France antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42. Italy antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 43. Italy antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 44. Italy antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 45. Italy antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 46. Spain antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 47. Spain antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 48. Spain antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 49. Spain antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50. Norway antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 51. Norway antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 52. Norway antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 53. Norway antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54. Denmark antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 55. Denmark antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 56. Denmark antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 57. Denmark antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58. Sweden antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 59. Sweden antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 60. Sweden antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 61. Sweden antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62. Asia Pacific antifungal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 63. Asia Pacific antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 64. Asia Pacific antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 65. Asia Pacific antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 66. Asia Pacific antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67. Japan antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 68. Japan antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 69. Japan antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 70. Japan antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71. China antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 72. China antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 73. China antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 74. China antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75. India antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 76. India antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 77. India antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 78. India antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79. Australia antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 80. Australia antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 81. Australia antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 82. Australia antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83. South Korea antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 84. South Korea antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 85. South Korea antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 86. South Korea antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87. Thailand antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 88. Thailand antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 89. Thailand antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 90. Thailand antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91. Latin America antifungal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 92. Latin America antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 93. Latin America antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 94. Latin America antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 95. Latin America antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 96. Brazil antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 97. Brazil antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 98. Brazil antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 99. Brazil antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 100. Argentina antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 101. Argentina antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 102. Argentina antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 103. Argentina antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 104. Middle East & Africa antifungal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 105. Middle East & Africa antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 106. Middle East & Africa antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 107. Middle East & Africa antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 108. Middle East & Africa antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 109. South Africa antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 110. South Africa antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 111. South Africa antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 112. South Africa antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 113. Saudi Arabia antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 114. Saudi Arabia antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 115. Saudi Arabia antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 116. Saudi Arabia antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 117. UAE antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 118. UAE antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 119. UAE antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 120. UAE antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 121. Kuwait antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 122. Kuwait antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 123. Kuwait antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 124. Kuwait antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Antifungal drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment snapshot
  • Fig. 10 Competitive landscape
  • Fig. 11 Antifungal drugs market dynamics
  • Fig. 12 Antifungal drugs market: Porter's five forces analysis
  • Fig. 13 Antifungal drugs market: PESTLE analysis
  • Fig. 14 Drug Class market, 2018 - 2030 (USD Million)
  • Fig. 15 Azoles market, 2018 - 2030 (USD Million)
  • Fig. 16 Echinocandins market, 2018 - 2030 (USD Million)
  • Fig. 17 Polyenes market, 2018 - 2030 (USD Million)
  • Fig. 18 Allylamines market, 2018 - 2030 (USD Million)
  • Fig. 19 Others market, 2018 - 2030 (USD Million)
  • Fig. 20 Indication market, 2018 - 2030 (USD Million)
  • Fig. 21 Dermatophytosis market, 2018 - 2030 (USD Million)
  • Fig. 22 Aspergillosis market, 2018 - 2030 (USD Million)
  • Fig. 23 Candidiasis market, 2018 - 2030 (USD Million)
  • Fig. 24 Others market, 2018 - 2030 (USD Million)
  • Fig. 25 Dosage Form market, 2018 - 2030 (USD Million)
  • Fig. 26 Oral Drugs market, 2018 - 2030 (USD Million)
  • Fig. 27 Ointments market, 2018 - 2030 (USD Million)
  • Fig. 28 Powders market, 2018 - 2030 (USD Million)
  • Fig. 29 Others market, 2018 - 2030 (USD Million)
  • Fig. 30 Distribution Channel market, 2018 - 2030 (USD Million)
  • Fig. 31 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 32 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 33 Other pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 34 Antifungal drugs market revenue, by region
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. country dynamics
  • Fig. 38 U.S. antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 39 Canada country dynamics
  • Fig. 40 Canada antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 41 Mexico country dynamics
  • Fig. 42 Mexico antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 43 Europe antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 44 UK country dynamics
  • Fig. 45 UK antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 46 Germany country dynamics
  • Fig. 47 Germany antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 48 France country dynamics
  • Fig. 49 France antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 50 Italy country dynamics
  • Fig. 51 Italy antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 52 Spain country dynamics
  • Fig. 53 Spain antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 54 Norway country dynamics
  • Fig. 55 Norway antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 56 Sweden country dynamics
  • Fig. 57 Sweden antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 58 Denmark country dynamics
  • Fig. 59 Denmark antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 61 Japan country dynamics
  • Fig. 62 Japan antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 63 China country dynamics
  • Fig. 64 China antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 65 India country dynamics
  • Fig. 66 India antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 67 Australia country dynamics
  • Fig. 68 Australia antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 69 South Korea country dynamics
  • Fig. 70 South Korea antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 71 Thailand country dynamics
  • Fig. 72 Thailand antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 73 Latin America antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 74 Brazil country dynamics
  • Fig. 75 Brazil antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 76 Argentina country dynamics
  • Fig. 77 Argentina antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 78 MEA antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 79 South Africa country dynamics
  • Fig. 80 South Africa antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 81 Saudi Arabia country dynamics
  • Fig. 82 Saudi Arabia antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 83 UAE country dynamics
  • Fig. 84 UAE antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 85 Kuwait country dynamics
  • Fig. 86 Kuwait antifungal drugs market, 2018 - 2030 (USD Million)
  • Fig. 87 Company categorization
  • Fig. 88 Company market position analysis, 2024
  • Fig. 89 Strategic framework